Company intelligence / Profile preview

Proteo, Inc.

Irvine, California, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Elafin (Tiprelestat) has completed Phase 1 safety/tolerability trial (subcutaneous, healthy volunteers) in 2019 with no severe adverse events; prior studies include EMPIRE trial for CABG (completed 2015); orphan drug designations obtained; preclinical support for PAH.

Therapeutic areas: ImmunologyCardiovascularPulmonologyGastroenterologyOncology
Modalities: Recombinant protein
Industry: Biotech

Partnerships

ARTES Biotechnology GmbH

Beyond the preview

Go deeper on Proteo, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteo, Inc..

Explore the full profile